首页> 外文期刊>BMC Musculoskeletal Disorders >Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality
【24h】

Alterations in osteoclast function and phenotype induced by different inhibitors of bone resorption - implications for osteoclast quality

机译:不同骨吸收抑制剂诱导的破骨细胞功能和表型改变-对破骨细胞质量的影响

获取原文
           

摘要

Background Normal osteoclasts resorb bone by secretion of acid and proteases. Recent studies of patients with loss of function mutations affecting either of these processes have indicated a divergence in osteoclastic phenotypes. These difference in osteoclast phenotypes may directly or indirectly have secondary effects on bone remodeling, a process which is of importance for the pathogenesis of both osteoporosis and osteoarthritis. We treated human osteoclasts with different inhibitors and characterized their resulting function. Methods Human CD14 + monocytes were differentiated into mature osteoclasts using RANKL and M-CSF. The osteoclasts were cultured on bone in the presence or absence of various inhibitors: Inhibitors of acidification (bafilomycin A1, diphyllin, ethoxyzolamide), inhibitors of proteolysis (E64, GM6001), or a bisphosphonate (ibandronate). Osteoclast numbers and bone resorption were monitored by measurements of TRACP activity, the release of calcium, CTX-I and ICTP, as well as by counting resorption pits. Results All inhibitors of acidification were equally potent with respect to inhibition of both organic and inorganic resorption. In contrast, inhibition of proteolysis by E64 potently reduced organic resorption, but only modestly suppressed inorganic resorption. GM6001 alone did not greatly affect bone resorption. However, when GM6001 and E64 were combined, a complete abrogation of organic bone resorption was observed, without a great effect on inorganic resorption. Ibandronate abrogated both organic and inorganic resorption at all concentrations tested [0.3-100 μM], however, this treatment dramatically reduced TRACP activity. Conclusions We present evidence highlighting important differences with respect to osteoclast function, when comparing the different types of osteoclast inhibitors. Each class of osteoclast inhibitors will lead to different alterations in osteoclast quality, which secondarily may lead to different bone qualities.
机译:背景技术正常的破骨细胞通过分泌酸和蛋白酶来吸收骨骼。对影响这两个过程的功能丧失的患者进行的最新研究表明,破骨细胞表型存在差异。破骨细胞表型的这些差异可能直接或间接地对骨重塑产生继发性作用,这一过程对于骨质疏松症和骨关节炎的发病机理都至关重要。我们用不同的抑制剂处理破骨细胞,并表征了它们的功能。方法采用RANKL和M-CSF将人CD14 +单核细胞分化为成熟的破骨细胞。在存在或不存在各种抑制剂的情况下,将破骨细胞培养在骨骼上:酸化抑制剂(bafilomycin A1,双叶蛋白,乙氧基唑酰胺),蛋白水解抑制剂(E64,GM6001)或双膦酸盐(伊班膦酸盐)。通过测量TRACP活性,钙,CTX-1和ICTP的释放以及计数吸收坑来监测破骨细胞数量和骨吸收。结果所有酸化抑制剂在抑制有机和无机吸收方面均具有同等效力。相反,通过E64抑制蛋白水解可有效降低有机物吸收,但仅适度抑制无机物吸收。单独使用GM6001不会对骨吸收产生很大影响。但是,当GM6001和E64结合使用时,观察到有机骨吸收完全消失,而对无机吸收没有很大影响。伊班膦酸消除了所有测试浓度[0.3-100μM]时的有机和无机吸收,但是,这种处理大大降低了TRACP活性。结论当比较不同类型的破骨细胞抑制剂时,我们提供的证据突出了破骨细胞功能方面的重要差异。每种破骨细胞抑制剂都会导致破骨细胞质量的变化,其次可能导致不同的骨质。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号